Category Archives: Cell Therapy

Orange, CA (PRWEB) September 30, 2013

TeleHealth, the leading stem cell therapy clinic on the West Coast, is now offering multiple treatments with stem cells for knee arthritis. The stem cell treatments are very exciting as they present the possibility of repairing and regenerating arthritis damage in the knees. The treatments are offered by Board Certified stem cell doctors at the clinic in outpatient, low risk procedures that are often covered by insurance. Call (888) 828-4575 for more information and scheduling.

Over the past few years, increasing studies are showing the benefits of regenerative medicine treatments for knee arthritis. This includes a study out of the Hospital for Special Surgery last year showing effectiveness of platelet rich plasma therapy for knee arthritis. Treatment options at TeleHealth include both platelet rich plasma therapy (PRP therapy) along with bone marrow derived stem cell injection therapy or fat derived stem cell therapy.

Often, the treatments are combined to produce maximum knee arthritis benefit and allow patients to avoid surgery, reduce pain and dramatically increase functional ability. While knee replacement surgery has been shown to have a high success rate, the components are not meant to last forever and there can be complications with the surgery.

Therefore, it makes sense to try conservative treatment prior such as with the regenerative medicine options at TeleHealth. Especially considering the stem cell treatments are often covered by insurance.

TeleHealths main stem cell clinic is located in Orange, CA, convenient to major freeways and not far from San Diego, Los Angeles, Santa Ana and Inland Empire. The highly skilled stem cell doctors at the clinic are Board Certified and have years of experience treating musculoskeletal conditions with stem cell treatments including shoulder arthritis, rotator cuff tendonitis, Achilles tendonitis, tennis elbow, muscle tears and much more.

Call (888) 828-4575 for more information and scheduling.

Read this article:
Southern California Stem Cell Therapy Clinic, TeleHealth, Now Offering Stem Cells for Knee Arthritis

Professor Arnold Caplan discusses mesenchymal stem cell therapy for multiple sclerosis
Professor Caplan is "The father of the mesenchymal stem cell (MSC)". In this clip, he describes a mouse experiment using human MSCs in a mouse model of MS. T...

By: http://www.cellmedicine.com

View original post here:
Professor Arnold Caplan discusses mesenchymal stem cell therapy for multiple sclerosis - Video

MANILA, PhilippinesStem cell therapy should only apply to skin grafting for burn patients and not for anti-aging purposes, according to the Food and Drug Administration (FDA).

Up to now, there is no evidence that stem cell therapy has anti-aging effects, said FDA acting Director General Kenneth Hartigan-Go.

The FDA recognizes only hematopoietic (pertaining to the formation and development of blood cells) stem cell transplantation, corneal resurfacing with limbal stem cells and skin regeneration with epidermal stem cells as generally accepted standards of health care.

Asked if this meant anti-aging stem cell therapies would not be allowed in the Philippines, Go said: It means that if the health claim is for burn patients, requirements that need to be submittedlike clinical trial reportsare expected to be complete, whereas if the claim is for anti-aging, then the requirements may be more extensive and intensive considering that products for anti-aging claims are still controversial.

Facility accreditation

The FDA said it had been continuously collaborating with the Department of Healths Bureau of Health Facilities and Services (BHFS) in accrediting facilities that deal with human cells, tissues, and cellular and tissue-based products (HCT/Ps), laboratory and therapeutic activities or services.

As of Sept. 24, 51 facilities have applied for accreditation, and 11 of these have been inspected by the BHFS, the FDA said.

No automatic approval

Submission of an application, however, does not necessarily result in automatic approval.

The FDA guidelines require that all stem cell and cellular-based treatments offered in the country should first pass the agencys standards for safety, efficacy and quality.

Continued here:
Stem cell therapy for burns, not aging, says FDA

Ben Moody of Evanescence talks HGH Stem Cell Therapy MetroMD Los Angeles

By: CARLY SMITHSON

Read more here:
Ben Moody of Evanescence talks HGH Stem Cell Therapy MetroMD Los Angeles - Video

In a step that brings stem cells closer to the clinic, researchers in Japan have found that transplanting reprogrammed stem cells into the brains of primates elicits little rejection by their immune systems.

Induced pluripotent stem cells (iPSCs) are created when skin cells, for example, are genetically reprogrammed to an embryonic-like state. This kind of stem cells holds great potential for the treatment of disease, since the cells are genetically identical to the patient they are taken from.

However, studies in rodents have suggested that the immune system may still recognize cells derived from iPSCs as foreign, and mount an attack on them. This has cast doubt on the feasibility of similar cell therapy for humans.

To test this in an animal more closely related to humans, researchers studied macaques. Using cells taken from the monkeys mouths or from their bloodstream, the researchers created iPSCs which they then, in turn, transformed into neurons. These neurons were of a specific kind: dopamine-producing neurons, the type depleted by Parkinsons disease.

Each monkey got six injections of these neurons into its brainsome which had been made from their own cells and others which were from another individual and therefore mismatched. The team could then see what kind of immune response each type produced.

Over subsequent months of observation, the monkeys showed very little immune response to transplants of their own cells. Their immune response was much higher in response to cells from another monkey.

The team also tracked how well the neurons survived after transplantation. They found that even when there was an immune response from the primate, the dopamine-producing neurons survived. The study is published today in Stem Cell Reports.

Trials using iPSCs to treat people with Parkinsons disease could therefore be on the horizon. These findings give a rationale to start autologous transplantationat least of neural cellsin clinical situations, says senior author Jun Takahashi of Kyoto University.

Image by Oliver Sved / Shutterstock

Visit link:
Stem Cell Therapy for Parkinson's Proves Safe in Primates

An unprecedented stem cell procedure that's been used on athletes overseas is now helping to improve the quality of life for mans best friend.

The technique is only available at one animal hospital in Louisiana.

Dale Landry loves his dog, Ratchet, unconditionally. He said he's a friend who's stuck by him through many of life's adventures.

"He comes to my office; he's a very active dog. He's done water sports until about two years ago, rides in the boat, rides the Seado. He actually used to wakeboard with me," Landry said.

Ratchet has been a little less active lately. The almost 15-year-old labrador mix has recently been suffering from joint pain and hip arthritis.

"He's been more and more hunched in the back and crouched down in the hind end, so you could definitely tell he was having a little trouble getting up in the morning," said Dr. Gordy Labbe of the Metairie Small Animal Hospital.

Ratchet has been taking medication and has undergone laser treatments for a year, but Labbe tried a new option Wednesday in the form of stem cell therapy.

It's a breakthrough technique that has yet to be used on small animals. It's a new tool available to veterinarians to combat osteoarthritis and give hope to improving quality of life of canines, felines and equine patients.

Labbe is one of the 450 veterinarians across the nation to implement this American Veterinary Medical Association approved procedure.

The Metairie Small Animal Hospital is the only clinic in the state of Louisiana that offers the in-house technology.

Continued here:
Stem cell therapy improves lives of pets

Poway, California (PRWEB) September 24, 2013

Vet-Stem, Inc., the world's leading Regenerative Veterinary Medicine company, is pleased to announce that Pets Best Insurance plans provide coverage for Regenerative Stem Cell Therapy. Pets Best Insurance knows that with pets come vet bills, especially when a pet is suffering from the pain of injury or arthritis. Pets Best Insurance wants the best for pets and their owners and Vet-Stem offers the best in regenerative medicine for them. Pets suffering from pain of osteoarthritis, joint issues, and injuries of the muscle, tendon and ligament can now be given stem cell therapy.

Vet-Stem first offered stem cell therapy for dogs and cats in 2007. One of the success stories and stem cell advocates is part of the Pets Best Insurance family, Jetta, owned by Greg McDonald, CEO of Pets Best Insurance.

Jack L. Stephens, DVM and President/Founder of Pets Best Insurance talks about Gregs experience: "Our CEO had a wonderful experience utilizing Vet-Stem therapy in his twelve year old lab. He loved throwing, and she loved chasing, a ball every evening. But as she aged, she just could not do it due to severe arthritis. Surgery was not a viable alternative and he asked me about stem cell therapy. I told him we had seen claims with the treatment and it was covered with our insurance. He had it done, her condition very much improved and she was able to chase the ball again. Pets Best Insurance provides full coverage for Vet-Stem Regenerative Cell Therapy, in fact we were early adopters of providing coverage and paying for the therapy. Any procedure performed by practicing veterinarians that helps pets, we are in favor of.

"We are proud that so many dog owners and veterinarians have placed their trust in Vet-Stem Cell therapy. We feel a great sense of accomplishment knowing that there are thousands of dogs and dog owners who have experienced the benefit of stem cell technology. This practical and beneficial application of technology puts stem cell therapy into the present day instead of a future theoretical concept. The fact that Pets Best provides coverage for our therapy is an added plus and makes this a viable treatment option for many more pet owners," said Robert Harman, DVM, MPVM, Founder and CEO of Vet-Stem.

For more information about Pets Best Insurance visit http://www.petsbest.com

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

Go here to read the rest:
Pets Best Insurance Announces Stem Cell Therapy and Regenerative Veterinary Medicine by Vet-Stem, Inc. Covered by ...

The author has posted comments on this articleBiswarup Gooptu, ET Bureau | Sep 25, 2013, 09.19AM IST NEW DELHI: Demand for quality healthcare and easier access to capital have led to the launch of many startups working in such areas as new drug development, stem cell therapy and advanced diagnostics. This has made the sector one of the most vibrant in India's entrepreneurial ecosystem.

Delhi-based Invictus Technology, which develops drugs for cancer care, is due to begin pre-clinical trials. "These platinum-based drugs will be less toxic and more effective," said Shiladitya Sengupta, 40, cofounder of the startup launched in 2011. "We are not looking at simply treating cancer, we are looking to cure it," said Sengupta who is an assistant professor of medicine at Harvard Medical School. This is the third startup that he has cofounded after Mitra Biotech, a Bangalore-based company that develops technology for personalised cancer therapy and Vyome Biosciences, which addresses skin diseases.

Entrepreneurs like Sengupta are targeting India's $78 billion ( Rs 48,984 crore) healthcare market, which is one of the most under-penetrated globally.

Twenty-four-year-old Zoya Brar quit her job at Google India last year to set up Core Diagnostics, along with colleague Arghya Basu, 27. The company offers high-end diagnostic services for cardiology and oncology,

"In this space, it is the pipeline that matters, not revenue, when it comes to establishing valuation," said Brar whose startup has already received Rs 27 cr of seed funding from Artiman Ventures. The company is now looking to expand into endocrinology and full and partial genome sequencing services.

"There are some very innovative ideas coming out of India, but early investors need to take more risks in backing the ventures," said Amit Varma, managing partner of Quadria Capital, a healthcare-focused private equity fund.

Invictus has garnered venture capital funding in spite of not generating much cash flow. Backed by Navam Capital and Aarin Capital, the company is looking to earn revenue by licensing its product across markets by 2015.

"It's a valuation play. We want to come out with India's first blockbuster cancer drug, and if phase-I trials are successful, then the company can be valued at between $100 million ( Rs 628 cr) and $150 million ( Rs 942 cr)," said Sengupta. Support is also coming from large pharma companies and hospital chains.

Stempeutics Research, which offers affordable stem cell-based therapeutics for the treatment of osteoarthritis and cirrhosis of the liver, is backed by the Manipal Group which runs a network of educational institutions and hospitals in Karnataka.

The Bangalore-based venture is currently conducting Phase-II trials in India and Malaysia for three products: Stempeucel, which focuses on treating cardiovascular, orthopaedics and respiratory diseases; Stempeutron, a device used for cosmetic therapy and Stempeucare that helps in skin regeneration.

Go here to read the rest:
Startups do promising work in drug development, stem cell therapy and advanced diagnostics